Change of Adviser

26 March 2019

Venn Life Sciences Holdings Plc

("Venn" or the "Company")

Change of Adviser

Venn Life Sciences, an Integrated Drug Development Partner offering a combination of drug development expertise and clinical trial design and management to pharmaceutical, biotechnology and medical device organisations, announces the appointment of Arden Partners plc as the Company's Nominated Adviser and Joint Broker with immediate effect, alongside its existing Joint Broker and ESM Adviser, Davy.

Enquiries:

Venn Life Sciences Holdings Plc Tel: +353 1 5499 341Tony Richardson, Chief Executive Officer

Arden Partners (Nominated Advisor and Joint Broker) Tel: +44 (0)20 7614 5900John Llewellyn-Lloyd / Ruari McGirr / Benjamin Cryer

Davy (ESM Adviser and Joint Broker) Tel: +353 (0)1 679 6363Fergal Meegan / Matthew de Vere White (Corporate Finance)

About Venn Life Sciences

Venn Life Sciences is an Integrated Drug Development Partner offering a unique combination of drug development expertise and clinical trial design and management to pharmaceutical, biotechnology and medical device organisations. Venn have dedicated operations in France, Germany, the Netherlands, the UK, Ireland with partners across Europe and the US.

Further information in relation to Venn Life Sciences www.vennlifesciences.com

Venn life Science: [email protected]